Coherus BioSciences 将来の成長

Future 基準チェック /16

Coherus BioSciencesの収益は年間90.4%で減少すると予測されていますが、年間収益は年間5.8%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に42.6% 50.9%なると予測されています。

主要情報

-90.4%

収益成長率

-50.9%

EPS成長率

Biotechs 収益成長	27.5%
収益成長率	5.8%
将来の株主資本利益率	42.6%
アナリストカバレッジ	Good
最終更新日	16 Dec 2024

今後の成長に関する最新情報

Recent updates

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Dec 21

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

業績と収益の成長予測

NasdaqGM:CHRS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	318	-45	-73	-82	5
12/31/2025	279	-71	-34	-38	5
12/31/2024	256	10	-64	-87	7
9/30/2024	304	0	-63	-62	N/A
6/30/2024	308	-29	-56	-54	N/A
3/31/2024	302	-59	-154	-153	N/A
12/31/2023	257	-238	-176	-175	N/A
9/30/2023	211	-217	-229	-262	N/A
6/30/2023	182	-264	-213	-245	N/A
3/31/2023	183	-271	-225	-256	N/A
12/31/2022	211	-292	-246	-241	N/A
9/30/2022	239	-279	-231	-193	N/A
6/30/2022	276	-230	-180	-143	N/A
3/31/2022	304	-210	-121	-93	N/A
12/31/2021	327	-287	-39	-37	N/A
9/30/2021	364	-232	-90	48	N/A
6/30/2021	395	-165	-60	82	N/A
3/31/2021	443	-76	-16	142	N/A
12/31/2020	476	132	139	154	N/A
9/30/2020	489	162	113	139	N/A
6/30/2020	487	181	125	146	N/A
3/31/2020	435	145	84	99	N/A
12/31/2019	356	90	15	28	N/A
9/30/2019	232	-12	-38	-37	N/A
6/30/2019	121	-118	-136	-134	N/A
3/31/2019	37	-185	-184	-183	N/A
12/31/2018	N/A	-209	-160	-159	N/A
9/30/2018	N/A	-196	-143	-142	N/A
6/30/2018	N/A	-196	N/A	-141	N/A
3/31/2018	1	-208	N/A	-161	N/A
12/31/2017	2	-238	N/A	-200	N/A
9/30/2017	2	-265	N/A	-257	N/A
6/30/2017	165	-122	N/A	-278	N/A
3/31/2017	178	-137	N/A	-250	N/A
12/31/2016	190	-127	N/A	-253	N/A
9/30/2016	199	-104	N/A	-160	N/A
6/30/2016	44	-259	N/A	-158	N/A
3/31/2016	37	-248	N/A	-151	N/A
12/31/2015	30	-223	N/A	-108	N/A
9/30/2015	26	-200	N/A	-147	N/A
6/30/2015	35	-137	N/A	-92	N/A
3/31/2015	33	-103	N/A	-72	N/A
12/31/2014	31	-87	N/A	-24	N/A
9/30/2014	26	-73	N/A	14	N/A
6/30/2014	10	-86	N/A	41	N/A
3/31/2014	6	-70	N/A	37	N/A
12/31/2013	3	-54	N/A	15	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CHRSの収益 ( 5.8% ) US市場 ( 9.1% ) よりも低い成長が予測されています。

高い収益成長: CHRSの収益 ( 5.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CHRSの自己資本利益率は、3年後には非常に高くなると予測されています ( 42.6 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/20 14:05
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Coherus BioSciences, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Colleen Kusy	Baird
Balaji Prasad	Barclays
Balaji Prasad	Barclays

Coherus BioSciences 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 12%

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Recent updates

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million.

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss